Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Phase 2 in Moderate-to-Severe Atopic Dermatitis
NCT01979016Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2013
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Placebo qw with Dupilumab 200 mg qw (2 arms). Primary endpoint: Percent Change From Baseline in the Eczema Area Severity Index at 16 weeks. Started Dec 2013; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT01979016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01979016.